Renaissance Technologies
ACOR

Renaissance Technologies’s Acorda Therapeutics ACOR Stock Holding History

Renaissance Technologies’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-46,761
Closed -$618K – 4113
2024
Q1 		$618K Buy
46,761
+1,000
+2% +$14.5K ﹤0.01% 2777
2023
Q4 		$691K Sell
45,761
-300
-0.7% -$3.4K ﹤0.01% 2608
2023
Q3 		$690K Buy
46,061
+500
+1% +$7.53K ﹤0.01% 2549
2023
Q2 		$593K Buy
45,561
+1,296
+3% +$15.4K ﹤0.01% 2772
2023
Q1 		$519K Buy
44,265
+820
+2% +$13.6K ﹤0.01% 2869
2022
Q4 		$666K Buy
43,445
+655
+2% +$7.63K ﹤0.01% 2768
2022
Q3 		$256K Sell
42,790
-2,276
-5% -$19K ﹤0.01% 3274
2022
Q2 		$420K Buy
45,066
+9,705
+27% +$173K ﹤0.01% 3258
2022
Q1 		$1.14M Sell
35,361
-347
-1% -$13.6K ﹤0.01% 2651
2021
Q4 		$1.71M Sell
35,708
-528
-1% -$36.4K ﹤0.01% 2271
2021
Q3 		$3.33M Buy
36,236
+530
+1% +$44K ﹤0.01% 1706
2021
Q2 		$3.41M Sell
35,706
-5,014
-12% -$439K ﹤0.01% 1885
2021
Q1 		$3.97M Buy
40,720
+6,676
+20% +$820K ﹤0.01% 1799
2020
Q4 		$2.82M Buy
34,044
+2,061
+6% +$190K ﹤0.01% 1926
2020
Q3 		$1.98M Sell
31,983
-106
-0.3% -$7.99K ﹤0.01% 2145
2020
Q2 		$2.83M Buy
32,089
+234
+0.7% +$24.7K ﹤0.01% 1976
2020
Q1 		$3.56M Sell
31,855
-289
-0.9% -$56.9K ﹤0.01% 1755
2019
Q4 		$7.87M Sell
32,144
-1,659
-5% -$419K 0.01% 1596
2019
Q3 		$11.6M Sell
33,803
-4,180
-11% -$2.27M 0.01% 1292
2019
Q2 		$35M Buy
37,983
+4,555
+14% +$5.6M 0.03% 650
2019
Q1 		$53.3M Buy
33,428
+15,204
+83% +$27.4M 0.05% 478
2018
Q4 		$34.1M Buy
18,224
+7,596
+71% +$16.5M 0.04% 596
2018
Q3 		$25.1M Buy
10,628
+4,954
+87% +$15.3M 0.03% 799
2018
Q2 		$19.5M Buy
5,674
+3,945
+228% +$12.1M 0.02% 931
2018
Q1 		$4.91M Buy
+1,729
New +$5.18M 0.01% 1822
2017
Q1 		– Sell
-3,212
Closed -$7.25M – 3470
2016
Q4 		$7.25M Sell
3,212
-590
-16% -$1.4M 0.01% 1441
2016
Q3 		$9.53M Buy
3,802
+1,861
+96% +$5.55M 0.02% 1170
2016
Q2 		$5.94M Buy
1,941
+1,428
+278% +$4.64M 0.01% 1492
2016
Q1 		$1.63M Sell
513
-953
-65% -$3.96M ﹤0.01% 2344
2015
Q4 		$7.53M Buy
+1,466
New +$6.41M 0.02% 1180
2015
Q3 		– Sell
-2,369
Closed -$9.48M – 3423
2015
Q2 		$9.48M Sell
2,369
-289
-11% -$1.12M 0.02% 1001
2015
Q1 		$10.6M Buy
2,658
+2,207
+489% +$10.1M 0.02% 904
2014
Q4 		$2.21M Sell
451
-365
-45% -$1.57M 0.01% 1744
2014
Q3 		$3.32M Buy
816
+470
+136% +$1.76M 0.01% 1384
2014
Q2 		$1.4M Sell
346
-1,467
-81% -$5.98M ﹤0.01% 1909
2014
Q1 		$8.25M Sell
1,813
-274
-13% -$1.11M 0.02% 977
2013
Q4 		$7.31M Buy
+2,087
New +$8.14M 0.02% 965

Other funds holding ACOR

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies's ACOR Position: Q2 2024 in Review

Renaissance Technologies sold out of Acorda Therapeutics (ACOR) in Q2 2024, closing a stake of 46,761 shares — an estimated $618K sold.

Renaissance Technologies first reported a position in ACOR in Q4 2013 and held it in 37 quarters. The position peaked at $53.3M in Q1 2019. 2 funds tracked by Wall St. Rank hold ACOR as of Q2 2024.

  • Renaissance Technologies reported no remaining Acorda Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Renaissance Technologies sold 46,761 Acorda Therapeutics shares in Q2 2024, an estimated $618K.
  • Renaissance Technologies first reported a position in Acorda Therapeutics in Q4 2013 and held it in 37 quarters.
  • Renaissance Technologies's Acorda Therapeutics position peaked at $53.3M in Q1 2019.
  • 2 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2024.

Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.